OMNIlife science and Global Orthopaedic Technology sign licensing deal
OMNIlife science and Global Orthopaedic Technology have signed an exclusive licensing agreement for OMNI's APEX knee implants for Australia, New Zealand and South Africa.
The agreement will see Global Orthopaedic Technology acquire exclusive rights to manufacture, market and distribute the APEX knee implants in Australia, New Zealand and South Africa.
Global will continue to market OMNI's OMNIBotics robotic-assisted total knee and computer-assisted total hip replacement technology in the agreed markets under a separate distribution agreement. In addition, OMNI will continue to market Global's Paragon hip implants in the United States also under a separate distribution agreement.
"Licensing the knee implants to Global ensures the APEX Knee will continue to expand in the evidence-based Australian healthcare market and provide OMNI non-dilutive capital to support the demand for robotic-assisted total joint replacement products in the large US orthopedics market," said Rick Randall, OMNI CEO.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
